Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOneCDx as a Companion Diagnostic for Relay's Investigational FGFR2 Inhibitor, RLY-4008
Today Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process
Source: finanznachrichten.de